Are EGFR TKIs (Such as Tarceva) Effective in Lung Cancer Patients Who Are Wild Type EGFR? episode artwork

EPISODE · Sep 25, 2014 · 1 MIN

Are EGFR TKIs (Such as Tarceva) Effective in Lung Cancer Patients Who Are Wild Type EGFR?

from GRACEcast · host cancerGRACE Meetings

For patients with wild type EGFR, meaning there is no EGFR mutation, drugs like Tarceva (erlotinib) can have a small benefit, but Dr. Joan Schiller wants research to do better. February 2014

Episode metadata supplied by the publisher feed · Published Sep 25, 2014

Embed this episode

NOW PLAYING

Are EGFR TKIs (Such as Tarceva) Effective in Lung Cancer Patients Who Are Wild Type EGFR?

0:00 1:02

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

Frequently Asked Questions

How long is this episode of GRACEcast?

This episode is 1 minute long.

When was this GRACEcast episode published?

This episode was published on September 25, 2014.

Can I download this GRACEcast episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!